Mainly after the second cycle (19 of 25), paracentral ring-like subepithelial deposits, corneal haze, and filamentous keratitis occurred. HealthDay News — For patients receiving mirvetuximab ...
OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, and a panel of experts examined a series of unusual ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Patients treated with mirvetuximab require close follow-up with an ophthalmologist due to the ...
CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has found more than two of three women taking the drug experienced some type of ...
More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA’s label for Elahere (mirvetuximab soravtansine) warns of ...
MedPage Today on MSN
Eye issues common with ANCA-associated vasculitis
Conjunctivitis or episcleritis and scleritis comprised the most common eye manifestations, while cataracts (11.7%) and visual ...
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep ...
The current standard of care for herpetic dendrites in the United States includes topical trifluridine 1% every 2 hours and topical cycloplegia if an anterior chamber reaction is present. Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback